Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non‐small cell lung cancer harboring BRAF V600E mutation: A case report

Abstract In recent years, significant improvement has been made in the management of non‐small cell lung cancer (NSCLC), primarily driven by advances in targeted therapy and immunotherapy. Research on neoadjuvant targeted therapy has also experienced considerable development, primarily directed towa...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Zhicheng Huang, Yadong Wang, Bowen Li, Yuan Xu, Guanghua Huang, Yang Song, Ji Li, Lan Song, Jinhua Wang, Rongxi Wang, Naixin Liang, Shanqing Li
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2024-08-01
Schriftenreihe:	Thoracic Cancer
Schlagworte:	BRAF‐V600E neoadjuvant NSCLC
Online-Zugang:	https://doi.org/10.1111/1759-7714.15409
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!